|
61
|
Multiple-modified Low-Density Lipoprotein as Atherogenic Factor of patients' Blood: Development of Therapeutic Approaches to reduce blood Atherogenicity.
Nikiforov NG, Zakiev ER, Elizova NV, Sukhorukov VN, Orekhov AN.
Curr Pharm Des. 2017 Jan 24. [Epub ahead of print]
|
|
62
|
The phenomenon of atherosclerosis reversal and regression: Lessons from animal models.
Chistiakov DA, Myasoedova VA, Revin VV, Orekhov AN, Bobryshev YV.
Exp Mol Pathol. 2017 Feb;102(1):138-145. doi: 10.1016/j.yexmp.2017.01.013. Epub 2017 Jan 17.
|
|
63
|
Use of Primary Macrophages for Searching Novel Immunocorrectors.
Nikiforov NG, Elizova NV, Bukrinsky M, Dubrovsky L, Makeev VJ, Wakabayashi Y, Liu P, Foxx KK, Kruth HS, Jin X, Zakiev ER, Orekhov AN.
Curr Pharm Des. 2017 Jan 25. [Epub ahead of print]
|
|
64
|
Blood Serum Atherogenicity: Cellular Test for the Development of Anti-Atherosclerotic Therapy.
Myasoedova VA, Ivashinnikova GA, Sobenin IA, Ivanova EA, Orekhov AN.
Curr Pharm Des. 2017 Jan 2. [Epub ahead of print]
|
|
65
|
How do macrophages sense modified low-density lipoproteins?
Chistiakov DA, Melnichenko AA, Orekhov AN, Bobryshev YV.
Int J Cardiol. 2016 Dec 28. pii: S0167-5273(16)34815-X. doi: 10.1016/j.ijcard.2016.12.164. [Epub ahead of print]
|
|
66
|
[Modified circulating low-density lipoproteins: pathogenetic significance in angiology].
Babintseva YD, Karagodin VP, Orekhov AN.
Angiol Sosud Khir. 2016;22(4):17-22.
|
|
67
|
Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c.
Gomez Rosso L, Lhomme M, Meroño T, Dellepiane A, Sorroche P, Hedjazi L, Zakiev E, Sukhorukov V, Orekhov A, Gasparri J, Chapman MJ, Brites F, Kontush A.
Biochim Biophys Acta. 2016 Nov 2. pii: S1388-1981(16)30301-8. doi: 10.1016/j.bbalip.2016.10.014. [Epub ahead of print]
|
|
68
|
Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA, Orekhov AN, Bobryshev YV.
Int J Cardiol. 2016 Nov 9;227:66-82. doi: 10.1016/j.ijcard.2016.11.204. [Epub ahead of print]
|
|
69
|
Peroxisome proliferator-activated receptor (PPAR) gamma agonists as therapeutic agents for cardiovascular disorders: Focus on atherosclerosis.
Ivanova EA, Myasoedova VA, Melnichenko AA, Orekhov AN.
Curr Pharm Des. 2016 Nov 18. [Epub ahead of print]
|
|
70
|
CD68/macrosialin: not just a histochemical marker.
Chistiakov DA, Killingsworth MC, Myasoedova VA, Orekhov AN, Bobryshev YV.
Lab Invest. 2016 Nov 21. doi: 10.1038/labinvest.2016.116. [Epub ahead of print]
|
